β-Defensin 129 Attenuates Bacterial Endotoxin-Induced Inflammation and Intestinal Epithelial Cell Apoptosis

Kunhong Xie, Hongmei Xie, Guoqi Su, Daiwen Chen, Bing Yu, Xiangbing Mao, Zhiqing Huang, Jie Yu, Junqiu Luo, Ping Zheng, Yuheng Luo, and Jun He

Defensins have attracted considerable research interest worldwide because of their potential to serve as a substitute for antibiotics. In this study, we characterized a novel porcine β-defensin (pBD129) and explored its role in alleviating bacterial endotoxin-induced inflammation and intestinal epithelium atrophy. The pBD129 gene was cloned and expressed in Escherichia coli. A recombinant pBD129 protein was also purified. To explore its role in alleviating the endotoxin-induced inflammation, mice, with or without lipopolysaccharide (LPS) challenge were treated by pBD129 at different doses. The recombinant pBD129 showed significant antimicrobial activities against the E. coli and Streptococcus with a minimal inhibitory concentration (MICs) of 32 µg/mL. Hemolytic assays showed that the pBD129 had no detrimental impact on cell viabilities. Interestingly, we found that pBD129 attenuated LPS-induced inflammatory responses by decreasing serum concentrations of inflammatory cytokines, such as the IL-1β, IL-6, and TNF-α (P < 0.05). Moreover, pBD129 elevated the intestinal villus height (P < 0.05) and enhanced the expression and localization of the major tight junction-associated protein ZO-1 in LPS-challenged mice. Additionally, pBD129 at a high dose significantly decreased serum diamine oxidase (DAO) concentration (P < 0.05) and reduced intestinal epithelium cell apoptosis (P < 0.05) in LPS-challenged mice. Importantly, pBD129 elevated the expression level of Bcl-2-associated death promoter (Bcl-2), but down-regulated the expression levels of apoptosis-related genes such as the B-cell lymphoma-2-associated X protein (Bax), BH3-interacting domain death agonist (Bid), cysteinyl aspartate-specific proteinase-3 (Caspase-3), and caspase-9 in the intestinal mucosa (P < 0.05). These results suggested a novel function of the mammalian defensins, and the anti-bacterial and anti-inflammatory properties of pBD129 may allow it a potential substitute for conventionally used antibiotics or drugs.

Keywords: endotoxemia, inflammation, porcine β-defensin 129, intestinal epithelium, apoptosis

INTRODUCTION

Endotoxemia induced by bacterial endotoxins involves a series of responses, including secretion of pro-inflammatory mediators, expression of adhesion molecules, and multiple organ dysfunctions (1). Previous studies have indicated that endotoxemia usually caused destruction of tight junction integrity and intestinal epithelium apoptosis (2, 3), which subsequently led to disruption of
intestinal homeostasis and damage of the intestinal barrier functions (4, 5). The intestinal epithelium barrier not only contributes to absorption of nutrients, but also contributes to preventing pathogens and toxins from the intestinal lumen from entering circulation (6, 7). Damage of the intestinal epithelium barrier resulted in exposure of submucosa to a variety of pathogens, which subsequently activated the innate immune response and produced a large number of pro-inflammatory cytokines, such as the interleukin-1β (IL-1β), interleukin-6 (IL-6), and tumor necrosis factor-α (TNF-α) (8). These pro-inflammatory cytokines not only caused elevated intestinal permeability, but also induced intestinal epithelial cell apoptosis (9).

The defensins, expressed in a variety of epithelial cells, are classified into alpha, beta, and theta forms based on the intramolecular disulfide bond patterns between six cysteines (10, 11). These proteins are a well-characterized group of small, disulphide-rich, cationic peptides that are highly diverse in their sequences and structures (12). Previous studies indicated that the β-defensins possess multidirectional biological properties, including antiviral, antibacterial, and anti-inflammatory effects (13, 14). However, evidence is accumulating to show that β-defensins can also play a role in regulating innate immunity and maintaining intestinal health. For instance, the β-defensin 2 was reported to attenuate inflammation and mucosal lesions during the pathologic process of dextran sodium sulfate (DSS)-induced colitis (15). Moreover, the β-defensin 3 significantly decreased production of pro-inflammatory cytokines by macrophages upon Porphyromonas gingivalis lipopolysaccharide challenge (16). The porcine β-defensin 129 (pBD129), a newly isolated porcine β-defensin, was first identified in reproductive tissues and was found to be overexpressed in wild boars infected by mycobacteria (17, 18). Although numerous evidence indicates that multiple β-defensins can serve as a critical regulator for diverse biological events including immune responses (15–18), the involvement of pBD129 in regulating the inflammatory responses is just beginning to be explored.

In the present study, we explored the effect of pBD129 on inflammatory responses and intestinal epithelium barrier functions by using a mouse model. The pBD129 gene was cloned and expressed in Escherichia coli, and a recombinant pBD129 protein was purified and characterized in vitro. To explore its role in regulating the endotoxin-induced inflammation, mice, with or without LPS challenge were treated by the recombinant pBD129 at different doses. Our study suggests a novel function of the mammalian defensins, and will assist in rational target selection, alleviating the endotoxemia-induced inflammation and damage of the intestinal epithelium barriers.

**MATERIALS AND METHODS**

**Synthesis, Expression, and Purification of PBD129**

The porcine β-defensin 129 gene (GenBank accession No. NM_001129975.1) was synthesized and cloned into the Sac I/Hind III sites of pET32a(+) by Tsingke Biological Technology Co., Ltd. (Chengdu, China). The resulting plasmid [pET32a(+)-pBD129] was transformed into E. coli BL21(DE3). Cultivation of the E. coli BL21(DE3) was performed at 37°C in LB medium supplemented with ampicillin (100 µg mL⁻¹) at 200 rpm. After incubation to mid-log growth (OD600 of 1.0), 1 mM isopropyl-l-thiogalactopyranoside (IPTG) were added to induce the expression of pBD129 protein. Cells were harvested by centrifugation at 8,000 × g for 20 min at 4°C, and lysed by sonication in ice-water bath after suspending in Binding buffer (20 mM Tris-HCl, 0.5 M NaCl, 10 mM imidazole, pH 7.9). The supernatant of the cell lysate resulting from centrifugation at 8,000 × g for 30 min was applied to a Ni-NTA column (Shenggong, Shanghai). After washing to baseline absorbance with Binding buffer, the column was washed with Elution Buffer (20 mM Tris-HCl, 0.5 M NaCl, 500 mM imidazole, pH 7.9) at a flow rate of 1 mL/min. The fractions were collected and applied to 12% SDS-PAGE. The protein concentration was determined by the BCA assay (Beyotime, Shanghai, China). After dialyzing with sterile saline solution (0.09% [wt/vol] NaCl in distilled water), the purified protein pBD129 was stored at −80°C for further use.

**Mass Spectrometry Analysis**

The expressed protein band was excised from gel for LC-MS/MS mass spectrometry analysis. Briefly, after the gel plug was digested with trypsin, 10 µL of the peptide mixture was separated at a flow rate of 400 nL/min on a C18-reversed phase column. A prominent nano 2D chromatography system (Shimadzu Corp., Kyoto, Japan) was attached to the mass spectrometer microOTOF-QII (Bruker Corporation, Billerica, MA, USA). The data was collected using Bruker Daltonics microTOF control software 3.2 (Bruker Corporation) with the conditions 50–2,200 m/z scan range, 1,500 V capillary voltages, and 150°C drying argon gas temperature. Finally, the selected peptide masses were analyzed using Data Analysis software 4.1 (Bruker Corporation) and searched using the Mascot search engine version 2.3.01.

**Assays of the Antibacterial and Hemolytic Activities**

Three Gram-positive species (Streptococcus dysgalactiae ATCC 12394, Staphylococcus aureus CICC23656, and Bacillus subtilis), three Gram-negative bacterial species (E. coli DH5α, E. coli K88⁺, and Salmonella typhimurium CICC14028), and Pichia pastoris X33 were used for the measurement of the antibacterial activity. The minimum inhibitory concentration (MIC) was determined by the method as previously described (19). The bacteria were grown overnight at 37°C; the culture was then diluted using medium to a concentration of 1 × 10⁵ CFU/mL and seeded into a 96-well plate at a density of 100 µL/well. Recombinant pBD129 was serially diluted from 512 µg/mL by a factor of 2, and 100 µL/well was added to the 96-well plate. The same volume peptide solutions (100 µL) without bacteria were used as negative controls. The reaction system was incubated at 37°C for 24 h. The OD₆₀₀ nm was measured to calculate the MIC. The experiments were done in triplicates on the same plate. Moreover, hemolytic activity measurements were performed according to a previous study (20). Briefly, 10 mL whole porcine blood was centrifuged...
at 1,500 × g for 10 min at room temperature. The porcine blood cells were washed three times with PBS buffer (150 mM NaCl; 10 mM Na2HPO4/NaH2PO4, pH 7.4) and resuspended in PBS buffer (in a 25-fold diluted concentration of erythrocytes compared to blood). Subsequently, 150 µL aliquots were added to 150 µL peptide solutions (final concentration 0–256 µg/mL pBD-129) in polypropylene 96-well microtiter plates, and the mixture was incubated for 1 h at 37°C. After incubation, the plate was centrifuged for 5 min at 1,500 × g and 150 µL supernatant of each well was transferred to a new 96-well plate. Extinction was measured at 450 nm with UV-1100 spectrophotometer (Shanghai, China) and the percentage hemolysis was calculated by comparison with the control samples containing no peptide or 1% Triton X-100.

**Animal Trial**

The animal trial was approved by the Animal Welfare Committee of Sichuan Agricultural University (No. 20180718). Sixty male ICR mice (4 weeks old) were purchased from Chengdu Da Shuo laboratory animal Co., Ltd. (Chengdu, China), and used for a 3 × 2 factor design (n = 10). The mice were intraperitoneally injected by three doses of pBD129 (0, 4, and 8 mg/kg), and challenged by sterile saline or LPS. All animals were individually housed at 22 ± 2°C with a cycle of 12 h light/12 h dark, and free access to food and water. The injections of pBD129 were carried out for 6 days (once a day) via 1 ml insulin syringe (Braun, Melsungen, Germany). At 7 d, mice were either challenged (intraperitoneal injection) by sterile saline or LPS (Escherichia coli O55:B5; Sigma-Aldrich, SL, USA) at a dose of 10 mg/kg. Five hours after challenge, the mice were anesthetized via 20% O255:B5; Sigma-Aldrich, SL, USA) at a dose of 10 mg/kg. Then, the mice were dissected, the jejunum was dissected, the jejunal mucosa was scraped, and then filtered through a mesh to form a cell suspension. After washing twice with ice-cold PBS, the cell sample was made into a single cell suspension of 1 × 10^6 cells/mL. One hundred microlitre of the single cell suspension was centrifuged at 1,300 × g for 15 min to remove the supernatant, then the cells were stained with 5 µL of PI staining for 5 min at 4°C in the dark. Finally, detection of the cell apoptosis was completed within 1 h after the addition of 400 µL Annexin V binding buffer (1x).

**Immunofluorescence Analysis**

The jejunal tissue section was deparaffinized and rinsed with distilled water for 5 min. Tissue sections were then subjected to antigen retrieval by ethylenediaminetetraacetic acid (EDTA, 1 mol/L, pH 9.0, Goeddbio Technology Co., Ltd., Wuhan, China). Before overnight incubating at 4°C with rabbit anti-ZO-1 polyclonal antibody (Goeddbio Technology Co., Ltd., Wuhan, China), sections were blocked with 3% bovine serum albumin. The sections were washed three times with PBS (pH 7.4) for 5 min each time, and then goat anti-rabbit IgG-FITC secondary antibody (Goeddbio Technology Co., Ltd., Wuhan, China) was added thereto, followed by incubation at room temperature for 50 min in the dark. Then, sections were washed three times with PBS (pH = 7.4), and the nuclei were stained with 4′,6-diamidino-2-phenylindole (DAPI, Goeddbio Technology Co., Ltd., Wuhan, China) for 10 min at room temperature in the dark. Finally, the fluorescence of the sections was visualized by a confocal scanning microscope (Nikon Eclipse Ti-SR), and the images were taken using Nikon DS-U3 software.

**Detection of the Cell Apoptosis**

The proportion of apoptotic cells in isolated jejunal mucosal cells was determined by flow cytometry (CytoFlex, Beckman Coulter, Inc., Brea, CA, USA) using PE Annexin V Apoptosis Detection Kit I (Becton, Dickinson and Company, BD Biosciences, San Jose, CA, USA). First, the jejunal was dissected, the jejunal mucosa was scraped, and then filtered through a mesh to form a cell suspension. After washing twice with ice-cold PBS, the cell sample was made into a single cell suspension of 1 × 10^6 cells/mL. One hundred microltre of the single cell suspension was centrifuged at 1,300 × g for 15 min to remove the supernatant, then the cells were stained with 5 µL of Annexin-V-FITC fluorescent dye at 4°C in the dark. After 10 min, add 5 µL of PI staining for 5 min at 4°C in the dark. Finally, detection of apoptotic cells was completed within 1 h after the addition of 400 µL Annexin V binding buffer (1x).

**RNA Extraction and Real-Time PCR**

Total RNA was extracted from duodenal, jejunal, and ileal samples using TRIzol Reagent (TaKaRa, Dalian, China). The concentration and purity of total RNA were assayed by spectrophotometer (Beckman Coulter, DU800) at 260 and 280 nm. The ratio of absorption (260/280 nm) of samples was between 1.8 and 2.0. Then, each RNA sample was reverse-transcribed into cDNA using reverse transcriptase (Takara, Tokyo, Japan) after detection of RNA concentration and purity by spectrophotometer (Beckman Coulter, DU800). The PCR primer sequences were designed using Primer Premier 5.0 and are listed in Supplementary Table 1. Briefly, quantitative PCR

**Histopathological Assays**

Samples taken from the duodenum, jejunum, and ileum were used for histological analysis. The samples were fixed overnight in 4% paraformaldehyde and then dehydrated with different concentrations of ethanol. After dehydration, samples were embedded in paraffin and were subsequently cut into 4-µm thick sections. The prepared tissue sections were stained with hematoxylin and eosin (H&E) and sealed with a neutral gum. Villus height and crypt depth were determined by using an image processing and analysis system (Image-Pro Plus 6.0, Media Cybernetics, Inc., Bethesda, MD, USA), and a previously described calculation method were adopted (21).

**Serum Parameter Measurements**

Serum diamine oxidase (DOA) assays were performed with commercially available kits from Nanjing Jiancheng Bioengineering Institute (Nanjing, Jiangsu, China). Mouse tumor necrosis factor-α (TNF-α), interleukin-1β (IL-1β), and IL-6 enzyme-linked immunosorbent assay (ELISA) kits were obtained from Beijing Sizhengbai Biotechnology Co., Ltd (Beijing, China). In addition, the 3100-type automatic fluorescence quantitative analyzer (Hitachi Co., Tokyo, Japan) was used to determine the concentrations of Immunoglobulin G (IgG), Urea, Creatinine (Cre), C-reactive protein (CRP), and Alanine transaminase (ALT) in serum samples.
was performed by QuanStudio 6 Flex Real-Time PCR detection system (Applied Biosystems, Foster City, CA, USA), with a total of 10 µL of assay solution containing 5 µL SYBR Green mix (TaKaRa, Dalian, China), 0.2 µL Rox, 3 µL deionized H2O, 1 µL cDNA template, and 0.4 µL each of forward and reverse primers. The comparative Ct value method was used to quantify mRNA expression relative to β-actin expression (22).

**Determination of Cysteiny1 Aspartate-Specific Protease Activity**

The activity of caspase-3 and caspase-9 were determined using the Cysteiny1 aspartate-specific protease activity kit (Beyotime, Shanghai, China). To evaluate the caspase-3 and caspase-9 activity of the small intestine, tissue lysates were prepared after their respective treatment with various designated treatments. Assays were performed on 96-well microtiter plates by incubating 50 µL protein of tissue lysate per sample in 50 µL reaction buffer (1% NP-40, 20 mM Tris-HCl (pH 7.5), 137 mM NaCl and 10% glycerol) containing 10 µL caspase-3 substrate (Ac-DEVD-pNA) (2 mM) or 10 µL caspase-9 substrate (Ac-LEHD-pNA) (2 mM). Lysates were incubated at 37 ºC for 2 h. Samples were measured with the UV-1100 spectrophotometer (Shanghai, China) at an absorbance of 405 nm and 1 µg Cysteiny1 aspartate-specific protease hydrolyzes Ac-DEVD-pNA or Ac-LEHD-pNA within 1 h to produce 1 nmol of pNA represents U/µg.

**Statistical Analysis**

The individual mouse was used as the experimental unit, and all data were expressed as mean ± standard error (SEM). Statistical analysis was carried out using two-way ANOVA followed by Bonferroni’s multiple comparisons test using GraphPad Prism software (Version 7. GraphPad Software Inc., CA, USA).

**RESULTS**

**In vitro Assays for the Antibacterial Activity of pBD129**

pBD129 (Porcine β-defensin 129) was expressed in E. coli BL21 (DE3) and purified by using the Ni-NTA agarose column (Supplementary Figure 1). The purity of recombinant pBD129 was analyzed with Image Lab (Bio-Rad), and the results showed that the purity of recombinant pBD129 was 90%. The purified protein was identified by mass spectrometry (LC-MS/MS). After searching the amino acid sequence of pBD129 in the NCBI database (Accession No. NP_001123447.1), we found that the sequence coverage of the two protein sequences was more than 82%, indicating that the purified protein was porcine β-defensin 129 (Supplementary Figure 2). The MIC assays were carried out using two-way ANOVA followed by Bonferroni’s multiple comparisons test using GraphPad Prism software (Version 7. GraphPad Software Inc., CA, USA). The MICs of pBD129 were expressed as mean ± standard error (SEM). Statistical analysis was carried out using two-way ANOVA followed by Bonferroni’s multiple comparisons test using GraphPad Prism software (Version 7. GraphPad Software Inc., CA, USA).

**Effect of pBD129 on Serum Biochemical Parameters in Mice Upon LPS Challenge**

The serum parameters are presented in Table 2. LPS challenge significantly increased the serum concentrations of inflammatory cytokines such as the IL-1β, IL-6, and TNF-α (P < 0.05). However, pBD129 injection significantly decreased the serum concentrations of these inflammatory cytokines upon LPS challenge (P < 0.05). No significant changes of serum inflammatory cytokines were observed in mice without being LPS challenged (P < 0.05). Additionally, LPS challenge significantly increased the serum concentrations of ALT, CRP, Cre, and urea (P < 0.05). Amongst the LPS-challenged groups, pBD129 injection at a high dose (8 mg/kg) significantly decreased the serum concentrations of ALT, CRP, Cre, and urea (P < 0.05). Moreover, pBD129 injection at a lower lose (4 mg/kg) can also decrease the serum concentrations of urea and Cre (P < 0.05). Interestingly, mice with LPS challenge showed an acute reduction in serum IgG concentration (P < 0.01), but pBD129...
injection at 8 mg/kg significantly increased the serum IgG concentration ($P < 0.01$).

**Effect of pBD129 on Intestinal Morphology, Permeability, and Distribution of the Major Tight Junction-Associated Protein ZO-1**

LPS challenge resulted in atrophy of the intestinal mucosa (Figure 2). As compared to the control group (challenged by sterile saline), the LPS-challenged mice have a shedding epithelium and shortened villi in the small intestine (Table 3). However, the villus height in the jejunum and ileum were significantly elevated by pBD129 in the LPS-challenged mice ($p < 0.05$). Moreover, pBD129 significantly decreased the crypt depth and elevated the ratio of villus height/crypt depth in the small intestine ($p < 0.05$). To investigate the intestinal permeability, the serum DAO concentrations were determined (Table 2). We show that LPS challenge acutely increased the serum DAO concentrations ($p < 0.01$). However, pBD129 treatment at a higher dose (8 mg/kg) significantly

**TABLE 2 | Porcine ionsBACTERIAI pamellorated the Biochemical Parameters of Serum during Bacterial Endotoxin-induced pathology.**

| Item | Control | L-129 | H-129 | L-129 + LPS | H-129 + LPS | P-value |
|------|---------|--------|--------|-------------|-------------|---------|
| IL-1β (pg/mL) | 29.98 ± 9.76bc | 37.13 ± 10.12bc | 32.02 ± 12.48a | 198.86 ± 18.52a | 35.40 ± 6.15b | 38.88 ± 6.54b | <0.0001 | <0.0001 | <0.0001 |
| IL-6 (pg/mL) | 23.25 ± 7.02c | 24.71 ± 1.14c | 24.02 ± 0.83c | 1934.21 ± 13.16a | 199.11 ± 39.29b | 85.01 ± 12.79c | <0.0001 | <0.0001 | <0.0001 |
| TNF-α (pg/mL) | 28.89 ± 0.74b | 32.84 ± 1.11b | 31.62 ± 2.31b | 73.32 ± 5.56a | 40.79 ± 1.67b | 35.68 ± 1.40b | <0.0001 | <0.0001 | <0.0001 |
| ALT (mmol/L) | 43.25 ± 2.21b | 43.50 ± 6.08b | 37.50 ± 1.19b | 83.50 ± 5.06b | 80.00 ± 6.87a | 36.75 ± 2.75b | <0.0001 | <0.0001 | 0.0004 |
| CRP (mg/L) | 0.66 ± 0.02b | 0.75 ± 0.09b | 0.41 ± 0.16b | 3.83 ± 0.66b | 3.25 ± 0.45b | 1.38 ± 0.15b | 0.0029 | <0.0001 | 0.0175 |
| Cre (mmol/L) | 7.33 ± 0.08b | 7.70 ± 0.16bc | 8.86 ± 0.09bc | 11.00 ± 0.72ab | 8.99 ± 0.14bc | 9.08 ± 0.19bc | 0.0675 | <0.0001 | 0.0003 |
| Urea (mmol/L) | 7.99 ± 0.13d | 7.95 ± 0.25d | 8.10 ± 0.26d | 20.05 ± 0.18bc | 10.81 ± 1.14bc | 13.28 ± 0.22bc | <0.0001 | <0.0001 | <0.0001 |
| IgG (g/L) | 0.58 ± 0.05b | 0.66 ± 0.08ab | 0.88 ± 0.06a | 0.18 ± 0.05c | 0.44 ± 0.07bc | 0.55 ± 0.03c | 0.0001 | <0.0001 | 0.2915 |
| DAO (U/L) | 24.15 ± 0.86b | 25.07 ± 0.88b | 27.82 ± 1.61ab | 31.44 ± 0.60a | 27.46 ± 1.52ab | 25.46 ± 0.18b | 0.3584 | 0.0159 | 0.0025 |

Different lowercase letters indicate statistically significant differences from each other ($P < 0.05$).

Values of the IgG, Cre, CRP, ALT, and UREA are 4 replicates per treatment; Values of the IL-1β, IL-6, and TNF-α are 5 replicates per treatment; Values of the DAO is 3 replicates per treatment.

1. IgG, Immunoglobulin G; Cre, creatinine; CRP, C-reactive protein; ALT, Alanine transaminase; DAO, diamine oxidase; IL-1β, Interleukin-1β; IL-6, Interleukin-6; TNF-α, tumor necrosis factor-α.

2. Control, 200 μL sterile saline; LPS, 200 μL Lipopolysaccharide; L-pBD129, 200 μL of 0.6 mg/ml porcine β-defensin; H-pBD129, 200 μL of 1.2 mg/ml porcine β-defensin; L-pBD129 + LPS, 200 μL of 0.6 mg/ml pBD129 pretreated followed by LPS treated; H-pBD129 + LPS, 200 μL of 1.2 mg/ml pBD129 pretreated followed by LPS treated.

3. δ is the main effect of porcine β-defensin 129; V is the main effect of LPS infection; B*V is the interaction effect of the two main factors.

**FIGURE 2 | Histological evaluation of small intestine tissue after exposure to pBD129 (H&E; × 200).** (A) Representative H&E stained sections from the duodenum. (B) Representative H&E stained sections from the jejunum. (C) Representative H&E stained sections from the ileum. Non-pBD129, 200 μL Sterile saline; L-pBD129, 200 μL of 0.6 mg/ml porcine β-defensin 129; H-pBD129, 200 μL of 1.2 mg/ml porcine β-defensin 129; L-pBD129 + LPS, 200 μL of 0.6 mg/ml pBD129 pretreated followed by LPS treated; H-pBD129 + LPS, 200 μL of 1.2 mg/ml pBD129 pretreated followed by LPS treated.
TABLE 3 | Effects of Porcine β-defensin 129 on the intestinal morphology of mice.

| Item       | Control | L-129 | H-129 | LPS | L-129+LPS | H-129+LPS | B  | V  | B*V |
|------------|---------|-------|-------|-----|-----------|-----------|-----|----|-----|
| Duodenum   |         |       |       |     |           |           |     |    |     |
| VH, μm     | 478.10 ± 2.54ab | 466.27 ± 1.68a | 471.79 ± 6.25a | 413.88 ± 17.25b | 445.34 ± 7.10ab | 428.28 ± 16.51ab | 0.6529 < 0.0001 | 0.1510
| CD, μm     | 136.88 ± 5.20b | 140.10 ± 2.77b | 138.85 ± 0.81b | 181.04 ± 3.30a | 153.03 ± 3.30b | 146.39 ± 4.02b | 0.0005 < 0.0001 | 0.0001
| VH/CD      | 3.51 ± 0.12a  | 3.33 ± 0.08a   | 3.40 ± 0.06a   | 2.29 ± 0.09c   | 2.92 ± 0.09b   | 2.92 ± 0.06b   | 0.0113 < 0.0001 | 0.0002
| Jejunum    |         |       |       |     |           |           |     |    |     |
| VH, μm     | 398.03 ± 9.50ab | 370.33 ± 11.47ab | 392.49 ± 11.46a | 253.60 ± 13.07c | 342.34 ± 13.07ab | 325.02 ± 14.04ab | 0.0254 < 0.0001 | 0.0005
| CD, μm     | 117.51 ± 2.08b | 114.73 ± 2.84b | 114.86 ± 1.69b | 142.62 ± 6.95a | 125.35 ± 3.42ab | 118.84 ± 2.85b | 0.0059 < 0.0004 | 0.0302
| VH/CD      | 3.39 ± 0.07a  | 3.23 ± 0.09a   | 3.42 ± 0.12a   | 1.79 ± 0.14c   | 2.73 ± 0.08b   | 2.74 ± 0.10b   | 0.0003 < 0.0001 < 0.0001
| Ileum      |         |       |       |     |           |           |     |    |     |
| VH, μm     | 224.83 ± 3.22ab | 221.24 ± 3.70ab | 228.64 ± 2.99a | 168.30 ± 6.82c | 208.01 ± 3.76ab | 207.70 ± 1.55b | < 0.0001 < 0.0001 | < 0.0001
| CD, μm     | 86.04 ± 2.72c  | 93.24 ± 1.86c  | 93.82 ± 1.17c  | 120.91 ± 2.02a | 105.09 ± 0.54b  | 103.85 ± 1.00b  | 0.0247 < 0.0001 < 0.0001
| VH/CD      | 2.62 ± 0.12a  | 2.38 ± 0.07a   | 2.44 ± 0.05a   | 1.39 ± 0.06c   | 1.98 ± 0.05b   | 2.0 ± 0.03b   | 0.0150 < 0.0001 < 0.0001

Different lowercase letters indicate statistically significant differences from each other (P < 0.05).

1 Values are the means of 3 replicates per treatment.
2 VH villus height, CD crypt depth, VH/CD the ratio of villus height and crypt depth.
3 Control, 200 μL sterile saline; LPS, 200 μL Lipopolysaccharide; L-pBD129, 200 μL of 0.6 mg/mL porcine β-defensin; H-pBD129, 200 μL of 1.2 mg/mL porcine β-defensin 129; L-pBD129 + LPS, 200 μL of 0.6 mg/mL pBD129 pretreated followed by LPS treated; H-pBD129 + LPS, 200 μL of 1.2 mg/mL pBD129 pretreated followed by LPS treated.
4 B is the main effect of Porcine β-defensin 129; V is the main effect of LPS infection; B*V is the interaction effect of the two main factors.

FIGURE 3 | Evaluation of the localization of ZO-1 and DAPI (DNA) in the jejunum of mice by immunofluorescence. ZO-1 protein (red), DAPI staining (blue), and pooled ZO-1 protein and DAPI are provided. The scale bar represents 100 μm. The green arrows mark jejunum positive for ZO-1 expression. Control, 200 μL sterile saline; LPS, 200 μL Lipopolysaccharide; L-pBD129, 200 μL of 0.6 mg/mL porcine β-defensin; H-pBD129, 200 μL of 1.2 mg/mL porcine β-defensin 129; L-pBD129 + LPS, 200 μL of 0.6 mg/mL pBD129 pretreated followed by LPS treated; H-pBD129 + LPS, 200 μL of 1.2 mg/mL pBD129 pretreated followed by LPS treated.

Xie et al. β-defensin 129 Attenuates Epithelial Cell Apoptosis

---

increased the serum DAO concentration in LPS-challenge mice (P < 0.05). Importantly, we explored the distribution of the major tight junction-associated protein ZO-1 in jejunum by immunofluorescence analysis, and found that the localization of ZO-1 protein in the jejunum was significantly changed after LPS challenge (Figure 3). As compared to the control group, LPS challenge has resulted in decreased abundance of ZO-1 protein in the tight junction region, indicating the disruption...
of the tight junction. In contrast, the abundance of ZO-1 protein was significantly elevated and localized to the apical intercellular region of the intestinal epithelium in mice treated by pBD129.

Effect of pBD129 on Intestinal Epithelium Cell Apoptosis

We found that necrotic apoptosis in the intestinal mucosa was significantly changed after LPS challenge (Figure 4). As compared to the control group, LPS challenge has resulted in elevated necrotic apoptosis in the intestinal mucosa. In contrast, the necrotic apoptosis was significantly decreased in the intestinal epithelium in mice treated by pBD129. In addition, as shown in Figure 4 and Table 4, LPS challenge significantly increased the percentage of the early-stage apoptotic cells and the total apoptotic cells in the intestinal mucosa ($P < 0.05$). However, pBD129 significantly reduced the percentage of the early-stage apoptotic cells and the total apoptotic cells in the LPS-challenged mice ($P < 0.05$). Interestingly, the caspase-3 and caspase-9 activities in the small intestine were measured and, as shown in Table 5, LPS challenge significantly increased the activity of caspase 3 and 9. However, pBD129 reduced their activities in the LPS-challenged mice ($P < 0.05$).

Effect of pBD129 on Critical Genes Related to Inflammatory Response, Intestinal Barrier Functions, and Cell Apoptosis

As shown in Figure 5, LPS challenge significantly elevated the expression levels of inflammatory cytokines such as the IL-6, IL-1β, and TNF-α in the small intestine ($P < 0.01$). However, pBD129 significantly decreased their expression levels in the LPS-challenged mice ($P < 0.01$). The expression levels of critical tight junction proteins such as the ZO-1, Occludin, and Claudin-2 were determined. As shown in Figure 6, LPS challenge has resulted in down-regulation of ZO-1 and Occludin in the small intestine ($P < 0.01$). However, pBD129 significantly elevated their expression levels in the duodenum and jejunum mucosa. In contrast, pBD129 decreased the expression level of Claudin-2 in the small intestine ($P < 0.01$). We also investigated the expression levels of critical apoptotic-related
The pBD129 is a newly discovered porcine beta-defensin, which has been reported to play a critical role in the modulation of the adaptive component of the outer membrane of gram-negative bacteria for conventionally used antibiotics.

Antimicrobial activity assays showed that pBD129 has significant antimicrobial activity against the gram-positive bacteria (Streptococcus) and gram-negative bacteria (E. coli DH5α). The result is also consistent with previous studies on the porcine beta-defensins (28, 29). Both indicated that the porcine beta-defensins has a broad antibacterial spectrum. Moreover, we found that the pBD129 has a weak hemolytic activity, indicating that it is harmless to humans and animals, and may be tentatively used as a substitute for conventionally used antibiotics.

Lipopolysaccharide (LPS) is an important structural component of the outer membrane of gram-negative bacteria which triggers the systemic inflammation and induces damage of target organs such as kidneys, liver, and intestinal mucosa (30).

**DISCUSSION**

Apoptosis of intestinal epithelial cells induced by pathogens disrupts intestinal barrier functions (23). In recent years, the beta-defensins has attracted considerable research interest since it has been reported to play a critical role in the modulating the adaptive immunity and improving the intestinal barrier functions (24, 25). The pBD129 is a newly discovered porcine beta-defensin, which is highly expressed in the epithelial cells of the gastrointestinal mucosa (26, 27).

In this study, we explored the role of pBD129 in regulating the inflammatory responses and intestinal epithelium barrier functions in mice.

The pBD129 was successfully expressed in E. coli BL21 (DE3) and the soluble proteins in the periplasmic space were purified. A significant degree of overlap (82%) was observed between the proteins identified in the LC-MS/MS data sets, indicating that the purified protein was porcine beta-defensin 129. The pBD129 was up-regulated by LPS challenge, and it significantly decreased their expression levels in the LPS-challenged mice (P < 0.05).

**TABLE 4** | Effects of Porcine beta-defensin 129 on the Jejunal mucosal apoptosis of mice.

| Item | Control | Treatment  |
|------|---------|-----------|
|      | L-129   | H-129     |
| EP   | 0.92 ± 0.26b | 1.60 ± 0.63b |
| LP   | 5.70 ± 0.26 | 2.07 ± 1.33 |
| TP   | 6.62 ± 0.51b | 3.67 ± 1.26b |

**TABLE 5** | Effects of Porcine beta-defensin 129 on the intestinal cysteiny l aspartate-specific protease activity of mice.

| Item | Control | Treatment  |
|------|---------|-----------|
|      | L-129   | H-129     |
| Cas-3, U/µg | 178.84 ± 9.49c | 177.81 ± 9.98c |
| Cas-9, U/µg | 292.39 ± 26.81c | 282.09 ± 58.13c |

**TABLE 6** | Effects ofPorcine beta-defensin 129 on the Jejunal mucosal apoptosis of mice.

| Item | Control | Treatment  |
|------|---------|-----------|
|      | L-129   | H-129     |
| EP   | 0.92 ± 0.26b | 1.60 ± 0.63b |
| LP   | 5.70 ± 0.26 | 2.07 ± 1.33 |
| TP   | 6.62 ± 0.51b | 3.67 ± 1.26b |

**TABLE 7** | Effects of Porcine beta-defensin 129 on the intestinal cysteiny l aspartate-specific protease activity of mice.

| Item | Control | Treatment  |
|------|---------|-----------|
|      | L-129   | H-129     |
| Cas-3, U/µg | 178.84 ± 9.49c | 177.81 ± 9.98c |
| Cas-9, U/µg | 292.39 ± 26.81c | 282.09 ± 58.13c |

**TABLE 8** | Effects of Porcine beta-defensin 129 on the Jejunal mucosal apoptosis of mice.

| Item | Control | Treatment  |
|------|---------|-----------|
|      | L-129   | H-129     |
| EP   | 0.92 ± 0.26b | 1.60 ± 0.63b |
| LP   | 5.70 ± 0.26 | 2.07 ± 1.33 |
| TP   | 6.62 ± 0.51b | 3.67 ± 1.26b |

**TABLE 9** | Effects of Porcine beta-defensin 129 on the intestinal cysteiny l aspartate-specific protease activity of mice.

| Item | Control | Treatment  |
|------|---------|-----------|
|      | L-129   | H-129     |
| Cas-3, U/µg | 178.84 ± 9.49c | 177.81 ± 9.98c |
| Cas-9, U/µg | 292.39 ± 26.81c | 282.09 ± 58.13c |

**TABLE 10** | Effects of Porcine beta-defensin 129 on the Jejunal mucosal apoptosis of mice.

| Item | Control | Treatment  |
|------|---------|-----------|
|      | L-129   | H-129     |
| EP   | 0.92 ± 0.26b | 1.60 ± 0.63b |
| LP   | 5.70 ± 0.26 | 2.07 ± 1.33 |
| TP   | 6.62 ± 0.51b | 3.67 ± 1.26b |
In the present study, the serum concentrations of inflammatory cytokines such as the IL-1β, IL-6, and TNF-α were both elevated upon LPS challenge, indicating the success of model construction. Interestingly, pBD129 treatment significantly decreased the serum concentrations of these inflammatory cytokines which suggested the β-defensins may act as a negative regulator for inflammatory responses. This result is consistent with previous studies on a variety of animal species (31, 32). Moreover, pBD129 treatment at a high dose (8 mg/kg) significantly decreased the serum concentrations of ALT, CRP, Cre, and urea, which has been widely used as biological markers of kidney and hepatic functionality (33). Additionally, pBD129 treatment (8 mg/kg) significantly increased the serum IgG concentration, which is consistent with previous findings that the β-defensins can act as a positive immune regulator for animals (34).

The intestinal epithelium provides a protective barrier, preventing both pathogenic, and commensal bacteria from escaping from the intestinal lumen. But some enteric pathogens can induce permeability defects in gut epithelia by altering tight junction proteins, which allows the translocation of toxins via the mucosa to access the whole body, subsequently destroying the intestinal mucosal homeostasis (35, 36). Disruption of the intestinal epithelium impairs the nutrient digestion and absorption (37). In the present study, LPS challenge significantly decreased the villus height in the small intestine. However, pBD129 significantly elevated the villus height in the LPS-challenged mice. This is probably due to the reduced inflammatory cytokines, since the IL-1β, IL-6, and TNF-α were found to induce atrophy of intestinal mucosa and disruption of intestinal functions (38–40). The DAO is a catalytic enzyme which is mainly synthesized in the digestive tract and involved in the metabolism, oxidation, and inactivation of histamine and other polyamines such as putrescine and spermidine in animals (41). Importantly, the serum DAO concentration has been widely used as a biomarker of the intestinal permeability since it can be released into the blood circulation (42). In the present study, LPS challenge significantly elevated the serum DAO concentration, indicating the disruption of the intestinal epithelium barriers. However, pBD129 treatment at 8 mg/kg significantly decreased the serum DAO concentration in LPS-challenge mice, indicating a protective effect of the β-defensins on intestinal mucosal integrity.

The intestinal epithelial cells (IECs) are connected in the lateral membrane by forming the tight junction (TJs) (43). TJs are mainly composed of cytoplasmic scaffold proteins such as ZO-1,
transmembrane proteins including claudins, and attachment adhesion molecules (JAM) (5), which controls the paracellular permeability of small molecules (44). Previous studies have indicated that inflammatory stress (i.e., LPS challenge) significantly decreased the abundance of TJ proteins (45, 46). A similar result was observed in the present study. However, we found that the abundance of ZO-1 protein was significantly elevated and localized to the apical intercellular region of the intestinal epithelium in mice after pBD129 treatment. The result is consistent with a previous study on porcine beta-defensin-2 (PBD-2) in DSS-treated mouse model.

Apoptosis is a form of physiological cell death that is important for the renewal of intestinal mucosa cells. In severe intestinal pathology, breakdown of intestinal mucosa via accelerated apoptosis increases intestinal permeability (47, 48). Previous studies have indicated that infections or stresses can increase intestinal epithelial cell apoptosis (49, 50). In the present study, LPS challenge increased the percentage of the apoptotic cells in the intestinal mucosa. However, pBD129 treatment significantly reduced the percentage of the early-stage apoptotic cells and the total apoptotic cells in the intestinal mucosa from LPS-challenged mice. This is also probably due to the decreased inflammatory cytokines after pBD129 treatment, since the IL-1β and TNF-α were found to induce apoptosis via intrinsic mitochondrial apoptotic pathway (51–53).

To gain insights into the mechanisms behind the pBD129 modulated intestinal barrier functions, we explored the expression levels of some critical molecules involved in the regulation of inflammatory response and apoptosis. Interestingly, the pBD129 was found to significantly decrease the expression levels of several critical inflammatory cytokines (i.e., IL-1β, IL-6, and TNF-α) and tight junction proteins (i.e., ZO-1 and Occludin) in the intestinal mucosa. The result is consistent with previous studies using different animal species (54, 55). The Bcl-2 is localized to the outer membrane of mitochondria, where it plays a critical role in promoting cellular survival and inhibiting the actions of pro-apoptotic proteins (56). In the present study, pBD129 treatment significantly elevated the expression levels of Bcl-2 and down-regulated the expression levels of critical apoptotic genes (Bad, Bid, Bax, caspase-3, and caspase-9) in the intestinal mucosa of LPS-challenged mice. The Bad, Bid, and Bax contributed to programmed cell death by inducing mitochondrial cytochrome c release, which activates caspase-9 and then caspase-3 (57, 58). The caspase-3 and caspase-9 are responsible for executing cell death during the demolition phase of apoptosis (59, 60), and we also found that pBD129 treatment significantly
reduced the caspase-3 and caspase-9 activities in the small intestine of LPS-challenged mice. For all gene expression experiments (Figures 5–7), pBD129 has no dose-dependent effect, probably because the range of dose selection is not large, and a broad range of doses could be considered in the further study. In the present study, pBD129 significantly decreased the expression levels of caspase-3 and caspase-9 in the intestinal mucosa of LPS-challenged mice. These results offer a molecular basis for the pBD129 mediated cell apoptosis in the intestinal mucosa.

In conclusion, the pBD129 attenuates bacterial endotoxin-induced inflammatory responses and intestinal mucosa atrophy by reducing the secretion of inflammatory cytokines and the apoptosis of intestinal epithelial cells. Our results suggested a novel function of the mammalian defensins, and the antibacterial and anti-inflammatory properties of pBD129 may allow it a potential agent to prevent or alleviate the LPS-induced inflammation and damage of the intestinal epithelium barriers.

**DATA AVAILABILITY STATEMENT**

All datasets generated for this study are included in the manuscript/Supplementary Files.

**ETHICS STATEMENT**

This study was approved by the Animal Welfare Committee of Sichuan Agricultural University (No. 20180718).

**AUTHOR CONTRIBUTIONS**

KX and HX performed most of the experiments. GS conducted the preparation of the pBD129 protein experiment. KX was also in charge of preparing the manuscript. JH contributed to study design and revised the manuscript. DC, BY, XM, ZH, JY, JL, PZ and YL contributed to the sample collection.

**FUNDING**

This study was supported by the key Research and Development program of Sichuan Province (2018NZDZX0005) and the Youth Innovation teams of animal Feed Biotechnology of Sichuan Province (2016TD0028).

**ACKNOWLEDGMENTS**

We thank Yaqiang Dai, Qian Lin, and Lei Liu for their help in animal trial. We also convey our great appreciation to Quyuan Wang and Huifen Wang for their assistance during the experiments.

**SUPPLEMENTARY MATERIAL**

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fimmu.2019.02333/full#supplementary-material
REFERENCES

1. Jae-Won L, Yong-Jun C, Jun-Ho P, Jae-Young S, Yong-Soo K, Hee Jae L, et al. 3,4,5-trihydroxyxycinnamic acid inhibits lipopolysaccharide-induced inflammatory response through the activation of NRf2 pathway in BV2 microglial cells. Biomol Ther. (2013) 21:60–5. doi: 10.4062/biomolther.2012.091

2. Zhang XM, Morikawa A, Takahashi K, Jiang GZ, Kato Y, Sugiyama T, et al. Localization of apoptosis. (programmed cell death) in mice by administration of lipopolysaccharide. Microbiol Immunol. (1994) 38:669–71. doi: 10.1111/j.1348-0421.1994.tb01838.x

3. Ayala A, Herdon C, Lehman D, Ayala CD, Chaudry IH. Differential induction of apoptosis in lymphoid tissues during sepsis: variation in onset, frequency, and nature of the mediators. Blood. (1996) 87:4261–75.

4. Grimaldi D, Guivarch E, Neveux N, Fichet J, Pène F, Marx JS, et al. Markers of intestinal injury are associated with endotoxemia in successfully resuscitated patients. Resuscitation. (2013) 84:60–5. doi: 10.1016/j.resuscitation.2012.06.010

5. Suzuki T. Regulation of intestinal epithelial permeability by tight junctions. Cell Mol Life Sci. (2013) 70:631–59. doi: 10.1007/s00018-1012-1070-x

6. Turner JR. Intestinal mucosal barrier function in health and disease. J Physiol. (2010) 588:2357–67. doi: 10.1113/jphysiol.2009.182930

7. Halpern MD, Denning PW. The role of intestinal epithelial barrier function in the development of NEC. Tissue Barriers. (2015) 3:e1000707. doi: 10.1080/21683770.2014.1000707

8. Sanchezmunoz E, Dominguezlopez A, Yamamotofurusho JK. Role of cytokines in inflammatory bowel disease. World J Gastroentero. (2008) 14:4280–8. doi: 10.3748/wjg.v14.i15.4280

9. Chen S, Bu D, Da Y, Zhu J, Sun L, Zuo S, et al. GYY4137 ameliorates intestinal barrier injury in a mouse model of endotoxemia. Biochem Pharmacol. (2016) 118:59–67. doi: 10.1016/j.bcp.2016.08.016

10. Mao X, Qi S, Yu J, Chen D, Zn2+ and I-isoleucine induce the expressions of porcine β-defensins in IPEC-J2 cells. Mol Biol Rep. (2013) 40:1547–52. doi: 10.1007/s11033-012-2200-0

11. Wei HM, Lin LC, Wang CF, Lee YJ, Chen YT, Liao YD. Antimicrobial properties of an immunomodulator-15 kDa human granulysin. PLoS ONE. (2011) e105632. doi: 10.1371/journal.pone.0105632

12. Shafee TMA, Lay FT, Phan TK, Anderson MA, Hulett MD. Convergent evolution of defensin sequence, structure and function. Cell Mol Life Sci. (2017) 74:663–82. doi: 10.1007/s00018-016-2344-5

13. Hancock RE, Haney EF, Gill EE. The immunology of host defense peptides: beyond antimicrobial activity. Nat Rev Immunol. (2016) 16:321–34. doi: 10.1038/nri.2016.29

14. Huang F, Huang S. Differential effects of statins on inflammatory interleukin-8 and antimicrobial peptide human B-defensin 2 responses in salmonella-infected intestinal epithelial cells. Int J Mol Sci. (2018) 19:1650. doi: 10.3390/ijms19061650

15. Han F, Zhang H, Xia X, Xiong H, Song D, Zong X, et al. Porcine-defensin 2 attenuates inflammation and mucosal lesions in dextran sodium sulfate-induced colitis. Immunology. (2015) 149:1882–93. doi: 10.1049/jimmunol.1402300

16. Lyu J, Bian T, Chen B, Cui D, Li L, Gong L, et al. β-defensin 3 modulates macrophage activation and orientation during acute inflammatory response to Porphromonas gingivalis lipopolysaccharide. Cytokine. (2017) 92:48–54. doi: 10.1016/j.cyto.2016.12.015

17. Sang Y, Patil AA, Zhang G, Ross CR, Blecha F. Porcine host defense peptides: expanding repertoire and functions. Dev Comp Immunol. (2013) 39:334–43. doi: 10.1016/j.dci.2013.03.006

18. Li C, Xu T, Chen R, Huang X, Zhao Y, Bao Y, et al. Cloning, expression and characterization of antimicrobial porcine β-defensin 1 in Escherichia coli. J Proteome Res. (2013) 12:87–93. doi: 10.1021/pr300626b

19. Gao CY, Xu TT, Zhao QL, Li CL. Codon optimization enhances the expression of porcine β-defensin-2 in Escherichia coli. Genet Mol Res. (2015) 14:4978–88. doi: 10.4238/2015.May.12.1

20. Chun-Chieh H, Jin-Cherng L, Chien-Hsin C, Sheng-Chu K, Tur-Fu H. Yuwenet-021 suppresses LPS-induced endotoxemia and adjuvant-induced arthritis primarily through blockade of ROS formation, NFKB and MAPK activation. Biochem Pharmacol. (2013) 85:385–95. doi: 10.1016/j.bcp.2012.11.002

21. Shen Z, Fang L, Zhao L, Lei H. β-defensin 2 ameliorates lung injury caused by pseudomonas infection and regulates proinflammatory and anti-inflammatory cytokines in rats. Int J Mol Sci. (2014) 15:13372–87. doi: 10.3390/ijms15081372

22. Kohlgraf KG, Ackermann A, Lu X, Burnell K, Belanger M, Cavanaugh JE, et al. Defensins attenuate cytokine responses yet enhance antibody responses to Porphromonas gingivalis adsorbs in mice. Future Microbiol. (2010) 5:115–25. doi: 10.2217/fmb.09.107

23. Lasagna-Reeves C, Gonzalez-Romero D, Barria MA, Olmedo L, Clos A, Ramanujam VMS, et al. Bioaccumulation and toxicity of gold nanoparticles after repeated administration in mice. Biochem Biophys Res Co. (2010) 395:649–55. doi: 10.1016/j.bbrc.2010.02.046

24. Roberts JB, Schneerres R, Szu SC. Peripheral hypothesis: serum IgG antibody is sufficient to confer protection against infectious diseases by inactivating the inoculum. Infect Dis-Nor. (1995) 171:1387–98. doi: 10.1093/infdis/171.6.1387

25. Shui JW, Larange A, Kim G, Vela JL, Zahner S, Cherouhte H. HVEM signalling at mucosal barriers provides host defence against pathogenic bacteria. Nature. (2012) 488:222–5. doi: 10.1038/nature11242

26. Berkes J, Viswanathan VK, Sorkovic SD, Hecht G. Intestinal epithelial responses to enteric pathogens: effects on the tight junction barrier, ion transport, and inflammation. Nat Rev Microbiol. (2003) 5:263–73. doi: 10.1038/nrmicro1242

27. Ramanujam VMS, et al. Proinflammatory cytokines and IL-10 in inflammatory bowel disease and colorectal cancer patients. Arch Intestinal Ther Ex. (2009) 57:291–4. doi: 10.1007/s00005-009-0031-z
40. Kim J, Xu M, Xo R, Mates A, Wilson GL, Pearsall AW, et al. Mitochondrial …
41. Wen Y, Li X, Goretsky T, Weiss HL, Barrett TA, Gao T. Loss of PHLPP…
42. Williams JM, Duckworth CA, Watson AJ, Frey MR, Miguel JC, Burkit MD, et al. Experimental ulcerative colitis impairs antioxidant defense system in rat intestine. *Dig Dis Sci.* (2000) 45:1820–7. doi: 10.1023/A:1005565708038
43. Fusco A, Savio V, Cammarota M, Alfano A, Schiraldi C, Donnarumma G. Beta-defensin-2 and beta-defensin-3 reduce intestinal damage caused by *Salmonella typhimurium* modulating the expression of cytokines and enhancing the probiotic activity of *Enterococcus faecium*. *Clin Dev Immunol.* (2017) 2017:6976935. doi: 10.1155/2017/6976935
44. Groschwitz K, Hogan SP. Intestinal barrier function: molecular regulation and disease pathogenesis. *J Allergy Clin Immun.* (2009) 124:3–20. doi: 10.1016/j.jaci.2009.05.038
45. Li HL, Jin JM, Yang C, Wang P, Huang F, Wu H, et al. Isoastragaloside I suppresses LPS-induced tight junction disruption and monocyte adhesion on bEnd.3 cells via an activating Nrfl antioxidant defense system. *RSC Adv.* (2018) 8:464–71. doi: 10.1039/C7RA10246A
46. Cheng X, Yang Y, Yang H, Wang Y, Du G. Kaempferol alleviates LPS-induced neuroinflammation and BBB dysfunction in mice via inhibiting HMGBl release and down-regulating TLR4/MyD88 pathway. *Int Immunopharmacol.* (2018) 56:29–35. doi: 10.1016/j.intimp.2018.01.002
47. Yasuda T, Takeyama Y, Ueda T, Shinzeki M, Sawa H, Nakajima T, et al. Breakdown of intestinal mucosa via accelerated apoptosis increases intestinal permeability in experimental severe acute pancreatitis. *J Surg Res.* (2006) 135:18–26. doi: 10.1016/j.jss.2006.02.050
48. Assimakopoulos SF, Scopa CD, Vagianes CE. Pathophysiology of increased intestinal permeability in obstructive jaundice. *World J Gastroentero.* (2007) 13:6458–64. doi: 10.3748/wjg.v13.i48.6458
49. Williams JM, Duckworth CA, Watson AJ, Frey MR, Miguel JC, Burkitt MD, et al. A mouse model of pathological small intestinal epithelial cell apoptosis and shedding induced by systemic administration of lipopolysaccharide. *Dis Model Mech.* (2013) 6:1388–99. doi: 10.1242/dmm.013284
50. Wen Y, Li X, Goretsky T, Weiss HL, Barrett TA, Gao T. Loss of PHLPP protects against colitis by inhibiting intestinal epithelial cell apoptosis. *BRA-Bioenergetics.* (2015) 1852:2013–23. doi: 10.1016/j.bbadis.2015.07.012
51. Kim J, Xu M, Xo R, Mates A, Wilson GL, Pearsall AW, et al. Mitochondrial DNA damage is involved in apoptosis caused by pro-inflammatory cytokines in human OA chondrocytes. *Osteoarthr Cartilage.* (2010) 18:424–32. doi: 10.1016/j.joca.2009.09.008
52. Grunnet LG, Reid A, Tonnesen MF, Steven P, Lykke B, Joachim SR, et al. Proinflammatory cytokines activate the intrinsic apoptotic pathway in β-cells. *Diabetes.* (2009) 58:1807–15. doi: 10.2337/db08-0178
53. Zhang Z, Ding Y, Dai X, Wang J, Li Y. Epigallocatechin-3-gallate protects pro-inflammatory cytokine induced injuries in insulin-producing cells through the mitochondrial pathway. *Eur J Pharmacol.* (2011) 670:311–6. doi: 10.1016/j.ejphar.2011.08.033
54. Kiatsurayanon C, Niyonsaba F, Smithrithee R, Akiyama T, Usio H, Hara M, et al. Host defense. (Antimicrobial) peptide, human β-defensin-3, improves the function of the epithelial tight-junction barrier in human keratinocytes. *J Invest Dermatol.* (2014) 134:2163–73. doi: 10.1038/jid.2014.143
55. Robinson K, Deng Z, Hou Y, Zhang G. Regulation of the intestinal barrier function by host defense peptides. *Front Vet Sci.* 2:57. doi: 10.3389/fvets.2015.00057
56. Chipuk JE, Moldoveanu T, Llambi F, Parsons MJ, Green DR. The BCL-2 family reunion. *Mol Cell.* (2010) 37:299–310. doi: 10.1016/j.molcel.2010.01.025
57. Niquet J, Wasterlain CG. Bim, Bad, and Bax: a deadly combination in epileptic seizures. *J Clin Invest.* (2004) 113:960–2. doi: 10.1172/JCI21478
58. Korsmeyer SJ, Gross A, Harada H, Zha J, Wang K, Yin X M, et al. Death and survival signals determine active/inactive conformations of pro-apoptotic BAX, BAD, and BID molecules. *Cold Spring Harb Sym.* (1999) 64:343–50. doi: 10.1101/sqb.1999.64.343
59. Brentnall M, Rodriguez-Menocal L, De Guevara RL, Cepero E, Boise LH. Caspase-9, caspase-3 and caspase-7 have distinct roles during intrinsic apoptosis. *BMC Cell Biol.* (2013) 14:32. doi: 10.1186/1471-2121-14-32
60. Walsh IG, Cullen SP, Clare S, Lüthi AU, Christopher G, Martin SJ. Executioner caspase-3 and caspase-7 have distinct roles during intrinsic apoptosis. *BMCCell Biol.* (2013) 13:64. doi: 10.1186/1471-2121-14-32
61. Copyright © 2019 Xie, Xie, Su, Chen, Yu, Mao, Huang, Yu, Luo, Zheng, Luo and He. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

**Conflict of Interest:** The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.